MARKET

XTNT

XTNT

XTANT MEDICAL
AMEX

Real-time Quotes | Nasdaq Last Sale

1.780
+0.060
+3.49%
After Hours: 1.800 +0.02 +1.12% 18:38 06/11 EDT
OPEN
1.710
PREV CLOSE
1.720
HIGH
1.800
LOW
1.679
VOLUME
90.01K
TURNOVER
--
52 WEEK HIGH
6.58
52 WEEK LOW
0.7100
MARKET CAP
154.34M
P/E (TTM)
-5.9532
1D
5D
1M
3M
1Y
5Y
Xtant Medical to Present at the Canaccord Musculoskeletal Conference
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the Canaccord Musculoske...
GlobeNewswire · 05/13 12:00
Drug eluting stent market size is anticipated to reach around US$ 4,050 Mn by 2027 | ARC
pune, India, Wed, 12 May 2021 03:25:40 / Comserve Inc. / -- The global drug eluting stent market size is anticipated to reach around US$ 4,050 Mn by 2027 and...
Comserve · 05/12 07:27
BRIEF-Xtant Medical Announces Q1 Revenue Of $12.5 Mln
reuters.com · 05/11 12:51
BRIEF-Xtant Medical Holdings Files For Mixed Shelf Of Up To $150 Mln
reuters.com · 05/11 12:29
Xtant Medical Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 11, 2021 / Xtant Medical Holdings, Inc. (NYSE:XTNT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 11, 2021 at 9:00 AM Eastern Time.
ACCESSWIRE · 05/11 12:15
Xtant Medical Announces First Quarter 2021 Financial Results
BELGRADE, Mont., May 11, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results fo...
GlobeNewswire · 05/11 12:05
Xtant Medical Files $150 Million Shelf Registration Statement
BELGRADE, Mont., May 11, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today it has filed a universal shelf re...
GlobeNewswire · 05/11 12:00
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 05/11 11:54
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XTNT. Analyze the recent business situations of XTANT MEDICAL through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XTNT stock price target is 1.000 with a high estimate of 1.000 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 14
Institutional Holdings: 11.86M
% Owned: 13.68%
Shares Outstanding: 86.71M
TypeInstitutionsShares
Increased
4
22.60K
New
1
15
Decreased
2
5.68K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.10%
Healthcare Equipment & Supplies
+0.06%
Key Executives
President/Chief Executive Officer/Director
Sean Browne
Chief Financial Officer/Vice President - Finance
Greg Jensen
Chief Operating Officer
Darrel Holmes
Senior Vice President
Kevin Brandt
Chief Scientific Officer
Gregory Juda
Director
John Bakewell
Director
Michael Eggenberg
Director
Robert McNamara
Director
Jeffrey Peters
Director
Matthew Rizzo
No Data
  • All
  • Financials
  • Insiders
More
About XTNT
Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.

Webull offers kinds of Xtant Medical Holdings Inc stock information, including AMEX:XTNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XTNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XTNT stock methods without spending real money on the virtual paper trading platform.